 Applied Molecular Transport Inc NASDAQ: AMTI will prioritize the advancement of AMT-101 into late-stage clinical development. It is preparing for the end of Phase 2 meetings with the FDA to advance AMT-101 to Phase 3 in chronic pouchitis. 